Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | PLA2G7 | Q13093 | 8/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 6/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29851513 | 1.00 | KIF11 (0.42) | KIF11PLA2G7MRGPRX4THRATHRB | |
| SCHEMBL29851798 | 0.89 | PLA2G7 (0.47) | PLA2G7 | |
| SCHEMBL9103130 | 0.89 | PLA2G7 (0.47) | PLA2G7 | |
| SCHEMBL14656299 | 0.87 | KIF11 (0.53) | KIF11PLA2G7ARPOLB | |
| SCHEMBL14671197 | 0.84 | KIF11 (0.42) | KIF11PLA2G7ARPOLB | |
| SCHEMBL14656288 | 0.84 | SOS1 (0.48) | POLBCASP6SOS1 | |
| SCHEMBL21855911 | 0.81 | TDP1 (0.43) | POLBCASP6SOS1 | |
| SCHEMBL29851804 | 0.81 | SCN9A (0.47) | MRGPRX4 | |
| SCHEMBL23193655 | 0.81 | SCN9A (0.47) | MRGPRX4 | |
| SCHEMBL14656089 | 0.81 | ALDH1A1 (0.39) | PLA2G7POLBCASP6SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630551-B2 | Endocyclic pyrimidinone compounds, and preparation methods, compositions and use thereof | NEUSCO BIOTECH LIMITED (CN) | 2026-05-19 | — | — | US | disclosed |
| CN-113912622-B | Tricyclic pyrimidinone compounds, methods of making, compositions and uses thereof | 上海纽思克生物科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230357268-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | NEUSCO BIOTECH LIMITED (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357268-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | NEUSCO BIOTECH LIMITED (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230271980-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | NEUSCO BIOTECH LIMITED (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271980-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | NEUSCO BIOTECH LIMITED (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230242532-A1 | TETRACYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | NEUSCO BIOTECH LIMITED (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242532-A1 | TETRACYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | NEUSCO BIOTECH LIMITED (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230212168-A1 | ENDOCYCLIC PYRIMIDINONE COMPOUNDS, AND PREPARATION METHODS, COMPOSITIONS AND USE THEREOF | NEUSCO BIOTECH LIMITED (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212168-A1 | ENDOCYCLIC PYRIMIDINONE COMPOUNDS, AND PREPARATION METHODS, COMPOSITIONS AND USE THEREOF | NEUSCO BIOTECH LIMITED (CN) | 2023-07-06 | — | — | US | disclosed |
| EP-4180436-A1 | TRICYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | Neusco Biotech Limited (CN) | 2023-05-17 | — | — | EP | disclosed |
| EP-4174070-A1 | TRICYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | Neusco Biotech Limited (CN) | 2023-05-03 | — | — | EP | disclosed |
| CN-113666930-B | Bridged pyrimidone compounds, preparation method, composition and application thereof | 上海纽思克生物科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-112574221-B | Tetracyclic pyrimidinone compounds, preparation method, composition and application thereof | 上海纽思克生物科技有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-113912622-A | Tricyclic pyrimidone compounds, preparation method, composition and application thereof | 上海纽思克生物科技有限公司 | 2022-01-11 | — | — | CN | disclosed |
| WO-2022001881-A1 | TRICYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | 上海纽思克生物科技有限公司 | 2022-01-06 | — | — | WO | disclosed |
| CN-113861220-A | Tricyclic pyrimidone compounds, preparation method, composition and application thereof | 上海纽思克生物科技有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-113666930-A | Bridged pyrimidone compounds, preparation method, composition and application thereof | 上海纽思克生物科技有限公司 | 2021-11-19 | — | — | CN | disclosed |
| WO-2021228159-A1 | BRIDGED CYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, COMPOSITION CONTAINING SAME AND USE THEREOF | 上海纽思克生物科技有限公司 | 2021-11-18 | — | — | WO | disclosed |
| CN-112574221-A | Tetracyclic pyrimidinone compounds, preparation method, composition and application thereof | 上海纽思克生物科技有限公司 | 2021-03-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212168-A1 | ENDOCYCLIC PYRIMIDINONE COMPOUNDS, AND PREPARATION METHODS, COMPOSITIONS AND USE THEREOF | PLA2G1B, PLA2G5, PLA2G4B | KIF11 4435/4885PLA2G7 7/4885MRGPRX4 1132/4885 |
| US-12630551-B2 | Endocyclic pyrimidinone compounds, and preparation methods, compositions and use thereof | LPAR1, PLA2R1, LPAR2 | KIF11 4741/4885PLA2G7 20/4885MRGPRX4 877/4885 |
| US-20230242532-A1 | TETRACYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | PLA2G1B, PLA2G5, PLA2G7 | KIF11 2739/4885PLA2G7 3/4885MRGPRX4 1696/4885 |
| US-20230271980-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | PLA2G1B, PLA2G4B, PLA2G4A | KIF11 4431/4885PLA2G7 5/4885MRGPRX4 693/4885 |
| US-20230357268-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | PLA2G1B, PLA2G4B, PLA2G5 | KIF11 4347/4885PLA2G7 5/4885MRGPRX4 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.